Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

FDA approves Nanowear’s cloth-based diagnostic monitoring platform

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media PackNow

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Medline Launches AI-Powered Supply Chain Platform...

Medline Industries has unveiled a new artificial intelligence-driven supply...

DOJ Launches West Coast Strike Force...

The United States Department of Justice has launched a...

AI Emergency Triage Study Shows Superior...

A Harvard-led study has found that advanced artificial intelligence...

Nanowear has secured class II 510(k) clearance from the US Food and Drug Administration (FDA) for its SimpleSENSE cloth-based diagnostic platform.

Claimed to be the first-of-its-kind, SimpleSENSE is a multi-parameter remote diagnostic undergarment and machine learning digital platform that simultaneously and synchronously monitors and evaluates the heart, lungs, and upper vascular system.

The SimpleSENSE platform, which is gender-neutral and size adjustable, is developed to replace the digital stethoscope, multi-channel Holter monitor, Capnogram respiration machine.and blood pressure cuff.

SimpleSENSE enables to capture over 100 million data points per patient per day

SimpleSENSE serves as a diagnostic monitoring system to remotely capture over 100 million data points per patient per day across cardiac, pulmonary, and circulatory biomarkers.

With a rise in demand for telemedicine and remote diagnostic monitoring, SimpleSENSE offers a digital tool to evaluate medical data and trends between these biomarkers in an innovative way.

Nanowear intends to continue its SimpleSENSE clinical trials in diagnosing worsening heart failure and Covid-19, in addition to near-term commercialisation of SimpleSENSE platform.

Nanowear co-founder and CEO Venk Varadan said: โ€œSimpleSENSE marks the companyโ€™s second FDA 510(k) clearance and follows Nanowearโ€™s strategy of continued data-driven differentiation in the connected-care and remote diagnostic market.

โ€œIn the face of the unexpected and unprecedented Covid-19 public health emergency, Nanowear began working collaboratively with FDA to evaluate a broadened indication for use for SimpleSENSE.

โ€œOur platform can now efficiently serve the new need for remote diagnostics across primary care, acute illness and procedure, and chronic disease cases.โ€

In July 2019, Nanowear commenced NanoSENSE heart failure management and alert diagnostic validation study.

Nanowear is involved in the development of patented and cloth-based nanosensor technology for use in different applications, including cardiac, neurological, and industrial safety.

MEDICAL FAIR ASIA 2026
MEDICAL FAIR CHINA

Latest stories

Related stories

Medline Launches AI-Powered Supply Chain Platform in Partnership with Microsoft

Medline Industries has unveiled a new artificial intelligence-driven supply...

AI Emergency Triage Study Shows Superior Clinical Accuracy

A Harvard-led study has found that advanced artificial intelligence...

Johnson & Johnson to Acquire Atraverse Medical Platform

Johnson & Johnson has entered into a definitive agreement...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป